110 related articles for article (PubMed ID: 6368760)
61. [Phase II study of etoposide (VP-16) in the form of oral capsules for malignant lymphomas].
Konishi I; Kitani T; Nagai K; Kanamaru A; Kohsaki M; Masaoka T; Shibata H; Horiuchi A; Tsubaki K; Kawagoe H
Gan To Kagaku Ryoho; 1985 Jul; 12(7):1482-6. PubMed ID: 4015122
[TBL] [Abstract][Full Text] [Related]
62. Phase I study of oral etoposide in children with refractory solid tumors.
Mathew P; Ribeiro RC; Sonnichsen D; Relling M; Pratt C; Mahmoud H; Bowman L; Meyer W; Avery L; Crist W
J Clin Oncol; 1994 Jul; 12(7):1452-7. PubMed ID: 8021737
[TBL] [Abstract][Full Text] [Related]
63. Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
Stahel RA; Jost LM; Cerny T; Pichert G; Honegger H; Tobler A; Jacky E; Fey M; Platzer E
J Clin Oncol; 1994 Sep; 12(9):1931-8. PubMed ID: 7521907
[TBL] [Abstract][Full Text] [Related]
64. [VM-26 salvage therapy for refractory or recurrent germinal testicular cancers].
Miki T; Oda H; Saiki S; Kinouchi T; Kuroda M; Kiyohara H; Usami M; Kotake T
Hinyokika Kiyo; 1985 Sep; 31(9):1649-56. PubMed ID: 4083220
[TBL] [Abstract][Full Text] [Related]
65. High-dose etoposide (VP-16) in small-cell lung cancer.
Greco FA; Johnson DH; Hande KR; Porter LL; Hainsworth JD; Wolff SN
Semin Oncol; 1985 Mar; 12(1 Suppl 2):42-4. PubMed ID: 2983434
[TBL] [Abstract][Full Text] [Related]
66. The place of chemotherapy in the treatment of testicular tumors.
Golbey RB
JAMA; 1970 Jul; 213(1):101-3 passim. PubMed ID: 5467953
[No Abstract] [Full Text] [Related]
67. [Collaborative phase II study of etoposide (NK-171). Urological Cooperative Study Group of etoposide (NK-171)].
Gan No Rinsho; 1985 Jul; 31(8):944-52. PubMed ID: 4040986
[TBL] [Abstract][Full Text] [Related]
68. Autologous bone marrow transplantation following high-dose busulfan and VP-16 for advanced non-Hodgkin's lymphoma and Hodgkin's disease.
Rosenfeld CS; Przepiorka D; Schwinghammer TL; Buck DS; Bloom EJ; Shadduck RK
Exp Hematol; 1991 Jun; 19(5):317-21. PubMed ID: 2026183
[TBL] [Abstract][Full Text] [Related]
69. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer.
Hansen F; Malthe I; Krog H
Gynecol Oncol; 1990 Mar; 36(3):369-70. PubMed ID: 2318446
[TBL] [Abstract][Full Text] [Related]
70. VP-16-213 (etoposide): the mandrake root from Issyk-Kul.
Vogelzang NJ; Raghavan D; Kennedy BJ
Am J Med; 1982 Jan; 72(1):136-44. PubMed ID: 6277188
[TBL] [Abstract][Full Text] [Related]
71. Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B.
Nissen NI; Pajak TF; Leone LA; Bloomfield CD; Kennedy BJ; Ellison RR; Silver RT; Weiss RB; Cuttner J; Falkson G; Kung F; Bergevin PR; Holland JF
Cancer; 1980 Jan; 45(2):232-5. PubMed ID: 6985831
[TBL] [Abstract][Full Text] [Related]
72. [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].
Schmoll HJ; Niederle N; Achterrath W
Klin Wochenschr; 1981 Nov; 59(21):1177-88. PubMed ID: 7031350
[TBL] [Abstract][Full Text] [Related]
73. Chemotherapy of mediastinal germ cell tumors.
Reynolds TF; Yagoda A; Vugrin D; Golbey R
Semin Oncol; 1979 Mar; 6(1):113-5. PubMed ID: 572088
[No Abstract] [Full Text] [Related]
74. An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer.
Rubin J; Decker DA; Ahmann DL; Eagan RT; Ingle JN; Hahn RG
Oncology; 1980; 37(3):149-51. PubMed ID: 7360486
[TBL] [Abstract][Full Text] [Related]
75. A phase II study of oral VP-16-213 in non-seminomatous testicular cancer.
Cavalli F; Klepp O; Renard J; Röhrt M; Alberto P
Eur J Cancer (1965); 1981 Feb; 17(2):245-9. PubMed ID: 7262161
[No Abstract] [Full Text] [Related]
76. A phase II trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study.
Bennett JM; Lymann GH; Cassileth PA; Glick JH; Oken MM
Am J Clin Oncol; 1984 Oct; 7(5):471-3. PubMed ID: 6594926
[TBL] [Abstract][Full Text] [Related]
77. VP16-213 as a single agent in advanced testicular tumors.
Fitzharris BM; Kaye SB; Saverymuttu S; Newlands ES; Barrett A; Peckham MJ; McElwain TJ
Eur J Cancer (1965); 1980 Sep; 16(9):1193-7. PubMed ID: 7227446
[No Abstract] [Full Text] [Related]
78. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP 16-213) in patients with gestational choriocarcinoma and malignant teratoma.
Brindley CJ; Antoniw P; Newlands ES; Bagshawe KD
Cancer Chemother Pharmacol; 1985; 15(1):66-71. PubMed ID: 4039984
[TBL] [Abstract][Full Text] [Related]
79. Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group.
Kung F; Hayes FA; Krischer J; Mahoney D; Leventhal B; Brodeur G; Berry DH; Dubowy R; Toledano S
Invest New Drugs; 1988 Apr; 6(1):31-6. PubMed ID: 3410665
[TBL] [Abstract][Full Text] [Related]
80. Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer.
Crivellari D; Veronesi A; Magri MD; Tirelli U; Comoretto R; Barzan L; Caruso G; Carbone A; Grigoletto E
Tumori; 1985 Oct; 71(5):499-500. PubMed ID: 4060251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
